Healthpeak Properties remains a Buy, supported by strong earnings, attractive dividend, and an ongoing portfolio pivot despite macro headwinds. DOC delivered a robust Q2, beating FFO and revenue estimates, increasing guidance, and executing $1 billion in asset sales to strengthen liquidity. Valuation remains compelling, with intrinsic value estimated above current levels even under conservative estimates, supported by conservative AFFO growth and a high discount rate.